These innovative molecules represent a significant advancement in the therapy of type 2 diabetes. Retatrutide, a combined GLP-1 and GIP receptor agonist, demonstrates exceptional efficacy in lowering blood glucose https://ellamaxx148661.dm-blog.com/39235798/novel-glp-1-receptor-agonists-retatrutide-and-trizepatide